Prostate cancer with lytic bone metastases: (18)F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy - Abstract

Lytic bone metastases are rare in prostate cancer.

We here present 18 fluorine fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography computed tomography (PET-CT) images of a 67-year-old male patient with lytic metastases from prostate cancer. Repeat ¹⁸F-FDG PET-CT done 6 months later showed response to medical castration therapy. While the role of ¹⁸F-FDG PET-CT for sclerotic bone metastases in prostate cancer remains controversial, it appears to be useful for detection and response assessment of lytic prostate cancer metastases.

Written by:
Sharma P, Karunanithi S, Singh Dhull V, Jain S, Bal C, Kumar R.   Are you the author?
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

Reference: Indian J Nucl Med. 2013 Jul;28(3):178-9.
doi: 10.4103/0972-3919.119545

PubMed Abstract
PMID: 24250030

UroToday.com Bone Metastases Section